Against the backdrop of multiple trial failures, pharmas are joining forces to support a project by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to develop biosignatures for Alzheimer's disease and major depression, based on research about the role in inflammation in these conditions.
The Biomarkers Consortium is a not-for-profit group founded in 2006 by the Foundation for the National Institutes of Health, the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?